The success of any cancer treatment hinges on identifying the right molecular targets. Improved patient outcomes can be achieved through precision medicine. Biomarker testing guides targeted therapy in oncology, improving cancer care.

“What are my chances with this cancer?” is the wrong question. Here's what to ask instead.

In this eye-opening episode, Dr. Dino Prato, founder of Envita Medical Centers, explains why traditional and integrative cancer treatments often fail — and how precision-targeted care can completely upgrade and improve outcomes as seen in the published literature and clinical experience.

Patients from around the world come to Envita after being told there are “no more options.” What makes the difference? Targets. Not just type and stage — but real-time, molecular-level precision.

🎯 What You’ll Learn:

• Why averages and general protocols can mislead your care
• How genomic testing and immune profiling uncover the real drivers of cancer
• What biomarkers, transcriptomics, and spatial biology mean for your remission
• How to ask the 10 essential questions to assess your treatment plan

Dr. Prato introduces a smarter path to healing — built on data over dogma.

✅ Get Dr. Prato's FREE Pocket Checklist:

https://assets.ctfassets.net/7k9stkq2d5ky/5qDyGiwCkrfaJkeA6sy9QF/3fa18f2a2240cf6d43eff9fabe00c9bc/physician-question-checklist.pdf

Disclaimer
This podcast is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your licensed healthcare provider before making any medical decisions. Individual results will vary, and Envita Medical Centers does not guarantee outcomes. Some treatments discussed may not be FDA-approved or available in all locations. Testimonials are shared with patient consent and may not reflect typical results. Do not delay or disregard professional medical care based on the podcast's content. Certain treatments may be available only at Envita’s international clinic in Hermosillo, Mexico. No specific outcomes are promised or implied.
________________________________________
Outcomes Disclaimer
The results referenced from Envita's Precision Cancer Care: 35-Fold Improvement in Response Rates are from a retrospective analysis of 199 late-stage cancer patients treated at Envita Medical Centers between 2021 and 2023, as published in the Journal of Cancer Therapy. These outcomes are not guaranteed and will vary based on individual factors such as cancer type, stage, genetics, immunity and prior treatments. Any comparisons to standard care or clinical trials are based on published data and internal analysis, not head-to-head studies. Individual results will vary.

You can read the full peer-reviewed study at:

https://www.scirp.org/journal/paperinformation?paperid=132493